Clinical Trial Update: Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tucidinostat in combination with R-CHOP for newly diagnosed double-expressor diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Tucidinostat (tucidinostat)

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: Diffuse Large B-cell Lymphoma | Phase 3 | Status: COMPLETED